Developing and maintaining cell lines for therapeutic bioproduction and biomedical research requires efficiency and accuracy. By automating the processes and techniques used in biomolecular research, scientists can achieve standardization, which can improve the speed, quality, and cost of drug discovery.
The Indian government announced the development of a new low-cost vaccine proven effective against a diarrhea-causing virus that is one of the leading causes of childhood deaths across the developing world. The Indian manufacturer of the new rotavirus vaccine pledged to sell it for $1 a dose.
Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit. Merck also saw stronger sales of materials for liquid-crystal displays and raised its profit forecast, saying it would...
Optimer Pharmaceuticals said Monday that it has named Eric Sirota as its chief operating officer. The Jersey City, N.J., company said that Sirota has experience in building pharmaceutical brands and that his appointment fills a significant need at the company. Hank McKinnell, chairman and CEO of of Optimer, said the appointment allows him to focus on the strategic review process.
A subsidiary of India's largest pharmaceutical company has agreed to pay $500 million in fines and civil penalties for selling adulterated drugs and lying about tests of the medications to federal regulators. Prosecutors said the guilty plea by Ranbaxy USA Inc. represents the largest financial penalty by a generic drug company for violations of the Federal Food, Drug and Cosmetic Act, which prohibits the sale of impure drugs.
The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory and at Baxter International Inc., a U.S. based healthcare company, revealed it to be promising and well tolerated, according to a research paper published online in The Lancet Infectious Diseases.
Scientists have helped identify many of the biomarkers for Alzheimer’s disease that could potentially predict which patients will develop the disorder later in life. Now, studying spinal fluid samples and health data from 201 research participants, researchers have shown the markers are accurate predictors of Alzheimer’s years before symptoms develop.
In a surprise move Friday, federal health regulators denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued are more easily abused than its branded product. Endo's Opana ER is a long-acting narcotic drug used to treat moderate and and severe pain. Such medications are frequently crushed and then injected or snorted by drug abusers to achieve a euphoric effect.
The drugmakers Actavis Inc. and Warner Chilcott PLC say they are holding early discussions about a possible combination of the two companies. The companies say there is no guarantee that Actavis will make an offer for Warner Chilcott, however. Actavis expects to generate more than $8.1 billion in revenue this year while Warner Chilcott expects raise about $2.3 billion to $2.4 billion.
Eli Lilly and Co. said it will stop development of an experimental cancer drug after it failed in a late-stage clinical trial.The company was studying enzastaurin as a treatment for diffuse large B-cell lymphoma, a cancer that affects a type of white blood cell.
Pfizer Inc. may not pursue further development of Remoxy, an experimental pain drug that has been plagued with delays in regulatory approval. Durect Corp. developed Remoxy and licensed it to Pain Therapeutics Inc. who in turn sublicensed the drug to Pfizer.
The 61st ASMS Conference on Mass Spectrometry and Allied Topics begins on Sunday, June 9 with tutorial lectures at 5:00 pm and the opening session and plenary lecture at 6:45 pm. A welcome reception in the poster/exhibit hall will follow.
The National Center for Neurology and Psychiatry and drugmaker Nippon Shinyaku Co. will start a clinical trial of a drug to treat Duchenne muscular dystrophy, a genetic disease that affects around one in 3,500 boys, aiming to release it for sale in five years.
The National Association of Boards of Pharmacy has thrown its support behind a proposal giving the Food and Drug Administration authority over large compounding pharmacies, in an effort to head off more outbreaks tied to contaminated medications.
Dendreon Corp. said that sales of its prostate cancer therapy Provenge fell in the first quarter because of increased competition from two newer drugs. Regulators approved Medication's Xtandi in August, and Johnson & Johnson has received approval to market Zytiga for use against prostate cancer.